Full-Time

Head of Security

Confirmed live in the last 24 hours

Biorender

Biorender

201-500 employees

Online platform for scientific illustrations

Biotechnology
Education
Healthcare

Senior, Expert

Remote in USA + 1 more

More locations: Remote in Canada

Remote position open to candidates in the US and Canada.

Category
Cybersecurity
IT & Security

You match the following Biorender's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Has previously led a security team and wants to bring their expertise to a high-growth environment where security is paramount to our customers.
  • Has broad technical security leadership experience, is comfortable owning security end to end, and is ready to take the next step in managing and growing a team and program.
  • Bachelor’s or Master’s degree in Computer Science, Information Technology, Cybersecurity, or a related field.
Responsibilities
  • Own the company’s overall security strategy in alignment with product, customer, and industry needs.
  • Develop and implement comprehensive policies and systems to ensure the integrity, confidentiality, and availability of information.
  • Ensure cybersecurity policies and practices comply with laws, regulations, and contractual obligations.
  • Partner with engineering and product teams to align technology infrastructure with strategic goals, emphasizing efficiency, value creation, and data security.
  • Work with product leadership and customer-facing teams to understand security requirements and plan for future needs.
  • Determine and prioritize security features for the product to meet customer demands and best practices.
  • Develop and manage the Security budget in line with BioRender’s strategic objectives.
  • Conduct regular audits, risk assessments, and business continuity planning; oversee required recertifications.
  • Oversee security measures for AI systems, protecting against threats specific to artificial intelligence.
Desired Qualifications
  • Strong preference for candidates with an enterprise SaaS background and experience in a startup or high-growth environment.
  • Proven ability to work closely with security ICs to design, implement, and manage security initiatives.
  • Familiarity with full-stack/single-page web applications and the ability to contribute to security-focused design discussions.
  • Up to date on modern approaches to securing AI/ML-backed product features, including legal/terms considerations and system architecture.
  • Prior experience owning an end-to-end security function for a smaller company is a plus.
  • Extensive knowledge of security frameworks and a practical approach to balancing cybersecurity and compliance.
  • Awareness of current IT trends, cybersecurity threats, and risk management practices.
  • Exceptional leadership and communication skills, with the ability to motivate a team and translate complex security concepts for non-technical stakeholders.

BioRender provides an online platform for creating scientific illustrations tailored for the life sciences sector. Users can access thousands of pre-drawn icons and templates across more than 30 life sciences fields, allowing scientists, researchers, and educators to produce professional and visually appealing figures efficiently. The platform's user-friendly interface enables clients, including academic researchers, pharmaceutical companies, and educational institutions, to create figures for research papers, presentations, and educational materials with minimal effort. BioRender operates on a subscription model, offering various plans to suit different user needs, including enterprise solutions for larger organizations. The company's goal is to simplify the process of creating high-quality scientific illustrations, making it an essential resource for effective scientific communication.

Company Size

201-500

Company Stage

Series A

Total Funding

$16.7M

Headquarters

Toronto, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for digital communication boosts need for scientific visualization tools.
  • Growing interest in graphical abstracts enhances research visibility and accessibility.
  • Open-access publishing trend increases demand for high-quality, appealing figures.

What critics are saying

  • AI-driven design tools may reduce demand for BioRender's platform.
  • Increased competition from cheaper visualization platforms could erode market share.
  • Potential IP disputes over pre-drawn icons could lead to legal challenges.

What makes Biorender unique

  • BioRender offers a vast library of customizable icons and templates for scientists.
  • The platform provides a user-friendly interface for creating professional scientific figures.
  • BioRender serves diverse clients, including academia, biotech, and pharmaceutical companies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

3%

2 year growth

5%
PR Newswire
Nov 12th, 2024
Researchers Uncover New Role Of Mutant Proteins In Some Of The Deadliest Cancers

Findings could point to new ways to treat RAS-driven cancers BETHESDA, Md., Nov. 12, 2024 /PRNewswire/ -- Researchers at the National Institutes of Health (NIH) and their collaborators have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface. Mutant RAS, they found, helps to kick off a series of events involving the transport of specific nuclear proteins that lead to uncontrolled tumor growth, according to a study published Nov. 11, 2024, in Nature Cancer

PR Newswire
Apr 13th, 2023
Peel Therapeutics Reports Excessive Netosis Induction In Long Covid

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis

Labiotech
Aug 24th, 2022
Study Findings Could Lead To New Anti-Cancer Drugs

Cancer cells surround themselves with a cloud of adenosine, thereby inhibiting the immune system (left). Ceritinib stops the formation of adenosine. ATP accumulates and activates immune cells (right). Figure: Laura Schäkel/University of Bonn – created with BioRender.com. German scientists say a drug already approved for other purposes can negate how tumor cells protect themselves from the immune system

WFMZ
Jun 15th, 2020
BioRender launched Graphical Abstract Contest on Jun 15th 20'.

Today BioRender, creator of the first web-based graphical tool for scientists to create publication and presentation-ready figures, announced its inaugural Graphical Abstract Contest, to give scientists a way to promote their research and win prize rewards.